SYS-CON MEDIA Authors: Jason Bloomberg, Eric Brown, Bob Gourley, Sandi Mappic, RealWire News Distribution

News Feed Item

Cannabis Science (CBIS) Applauds Unprecedented United States Federal Government Approval of University Study of Medical Cannabis for Veterans Suffering from PTSD

Company Sees Move as Significant Federal Policy Shift in Medical Cannabis Research in the United States

COLORADO SPRINGS, Colo., March 19, 2014 /PRNewswire/ -- Cannabis Science, Inc. (NASDAQ OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, applauds federal government approval of a University of Arizona study of efficacy of medical cannabis in treating post traumatic stress disorder (PTSD).  Cannabis Science sees this approval by the U.S. Department of Health and Human Services as a watershed moment for federal authorization of medical cannabis research.

"As a premier medical cannabis pharmaceutical company, we welcome the federal government support of a significant patient study of the effectiveness of treating PTSD with medical cannabis.  While admittedly a first step, it is a substantial one that moves federal policy in the direction of permitting important patient-based research that we at CBIS believe will show the clear medical value of cannabis for many diseases and conditions," said Dorothy H. Bray, Ph.D., Director & CEO of Cannabis Science, Inc.

For more information about the approved study, please see the following links:

http://www.techtimes.com/articles/4525/20140319/federal-government-shows-greenlight-for-medical-marijuana-study-for-ptsd-treatment-of-veterans.htm

http://news.yahoo.com/marijuana-study-veterans-wins-federal-163051558.html

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com
[email protected]
[email protected]
Tel: 1.888.777.0658

Investment Inquiries:
Robert Kane, CFO & Director
[email protected]
Tel: 1.561.420.4824

SOURCE Cannabis Science, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.